Seagen: A Stellar Portfolio Anchor (NASDAQ:SGEN)


Artur Plawgo



It’s much better to purchase an exquisite firm at a good worth than a good firm at an exquisite worth. – Warren Buffett

Author’s Note: This article is an abridged model of an article initially revealed for members of the Integrated BioSci Investing market on September 28, 2022.

While you can also make money buying and selling biotech catalysts, your greatest features come from holding fastidiously chosen development bio-stocks all through many market cycles. After all, that is the place you will get your multi-bagger earnings. And, that is what the investing gurus like Warren Buffett or Charlie Munger would do. As you possibly can see, only some biotech companies would change into the massive biopharmaceuticals of the long run. One cause is that promising companies are inclined to get acquired. The different extra widespread cause is that subpar performers by no means develop into a big cap operator. As such, you must comply with the investing thesis (i.e., story) of your shares to see should you ought to maintain them for the lengthy haul.

That being stated, I’d prefer to revisit an organization that has nice long-term potential. Powered by 4 nice medicines, Seagen Inc. (NASDAQ:SGEN) is poised to get pleasure from virtually $1.7B in revenues for this yr. Despite large progress, there are lots of elementary enhancements to ship long-term upsides. In this analysis, I’ll function a elementary analysis of Seagen and share with you my expectation of this intriguing Phillip Fisher development equity.

SGEN chart


Figure 1: Seagen chart

About The Company

As traditional, I’ll current a short company overview for brand spanking new buyers. If you are aware of the agency, I counsel that you simply skip to the following part. I famous within the prior analysis,

Operating out of Bothell Washington, Seagen is concentrated on the event and commercialization of novel antibody-drug conjugates (“ADCs”) to serve the robust unmet want in varied most cancers indications. Of notice, ADCs work by linking a payload drug to an antibody that has binding-specificity to sure most cancers cells. As such, this results in improved drug specificity, stability, and efficiency. In harnessing the facility of ADCs, Seattle Genetics is brewing a strong therapeutic pipeline of permitted medicines and creating medication with completely different companions.



Figure 2: Therapeutic pipeline

Tracking Seagen’s Investment Thesis

Before continuing with the analysis, you must place Seagen into its acceptable funding class. That means, you possibly can higher monitor its progress and thereby know when to purchase, promote, or maintain. Here, Seagen matches into the “growth biotech” class. As such, you’d need to monitory any developments regarding its Big Four franchises (i.e., Padcev, Adcetris, Tukysa, and Tivdak). Growth for these permitted medication entails rising gross sales and development regarding label expansions.

Beyond the permitted medication, you need to be sure the vast majority of new developments (both natural or by way of partnership/acquisition) stays within the immuno-oncology (i.e., I/O) area of interest and regarding its know-how (i.e., ADC).

So lengthy as you see that development/improvement for the Big Four in addition to extra I/O and ADC, that your funding thesis (i.e., story) is understanding effectively.

LAVA Therapeutics Deal

Committed to long-term development past the permitted medicines, Seagen lately entered right into a partnership with LAVA Therapeutics again on September 26. Given {that a} development biotech is closely invested in long-term development, it is a good signal that your investing thesis is understanding. Hence, allow us to take a more in-depth take a look at this partnership.

Accordingly, Seagen would in-license the pre-clinical molecule from LAVA, i.e., LAVA-1223. Capturing the facility of the Gammabody know-how, LAVA-123 triggers a particular subset of T-cells — the bispecific gamma/delta (i.e., GD) T cell engagers — to focus on a extremely prevalent floor marker in stable tumors. Namely, that marker is the epidermal development issue receptor (i.e., EGFR).

You can consider LAVA-1223 as a sensible medication telling the GD T-cells to zone in on cancers having the EGFR on its floor whereas sparing regular cells. That confers large specificity and extremely efficacious most cancers decimation. With EGFR being discovered on many most cancers cells (colorectal, lung, head/neck), the potential of this first-in-class drug is large. Commenting on the deal, the interim CEO and CMO (Dr. Roger Dansey) remarked,

Seagen is dedicated to driving innovation to enhance the lives of individuals with most cancers, and this settlement represents the corporate’s entry right into a novel class of therapeutics which are designed to beat the challenges of normal T cell engagers by leveraging the exercise of a definite T cell subset. This unique license from LAVA offers Seagen with the chance to harness its experience in creating first-in-class focused most cancers therapies, together with the corporate’s international improvement and commercialization capabilities.

Gammabody platform


Figure 3: Gammabody platform mechanism of motion

Of particular deal phrases, Seagen would obtain the unique international license for LAVA-1223. In return, Seagen would pay LAVA $50M upfront plus $650M in potential improvement. That means, if LAVA-1223’s developments bear fruits (i.e., optimistic scientific outcomes and approval), LAVA can achieve as much as as a lot as $650M. On prime of that, there’s additionally ongoing royalties starting from single digits to mid-teens on future gross sales outcomes.

Riding Seagen’s deep experience in therapeutic developments and large expertise navigating the regulatory landscapes, you possibly can wager that this is able to give LAVA-1223 one of the best probabilities of success. If optimistic, LAVA will get to get pleasure from a part of the earnings with Seagen sooner or later. The $50M now would give the smaller firm (i.e., LAVA) a lot wanted money to fund their operations.

While it appears extremely in favor of LAVA, the hidden worth on this deal for Seagen is the rights to LAVA’s Gammabody platform for 2 extra tumor targets. Those two indications can procure extra blockbusters Seagen. As , the huge purposes of LAVA’s Gammabody platform (within the fingers of a extremely skilled innovator, Seagen) would considerably enhance the possibility that some (if not most) improvement would ship optimistic outcomes. According to the President and CEO of LAVA (Stephen Hurly),

LAVA is pioneering the event of gamma delta bispecific antibodies to deal with most cancers, and we’re happy to work with Seagen on this pursuit. The mixture of LAVA’s proprietary Gammabody platform and deep bispecific experience, with Seagen’s management in creating focused therapies for most cancers and commercialization infrastructure, makes this a great partnership to advance novel therapies for sufferers. This settlement permits LAVA to additional validate its platform in a second stable tumor product candidate, bringing us nearer towards our objective of producing efficient Gammabody medicines for most cancers sufferers. We sit up for working with Seagen to develop potential subsequent era most cancers therapies.

Zai Lab Collaboration

Asides from the stated cope with LAVA, Seagen additionally announced the partnership with Zai Lab on September 27 for Tivdak. As the primary and solely ADC permitted within the US for adults affected by metastatic cervical most cancers – with illness development on or after chemo – Tivdak is a perfect drug for Zai Lab so as to add to their oncology (i.e., most cancers) portfolio.

As you possibly can see, the collaboration would give Seagen $30M in upfront cost. Moreover, Seagen is about to achieve extra money on milestones (i.e., improvement, regulatory, and business). Furthermore, Seagen and its different collaborative associate Genmab (GMAB) would share 50/50 on the tiered gross sales royalty. As such, Seagen is about to revenue from three fonts. And, you possibly can admire {that a} partnership like this is able to give Seagen additional cash to spend money on different offers reminiscent of LAVA.

In a therapeutic launch, your drug ought to both be the primary, the one, or completely different from opponents for it to succeed. As you noticed, Tivdak is each the primary and solely of its variety permitted within the USA. As such, the possibilities are extremely in its favor. Back in 2021, the FDA granted Tivdak accelerated approval for recurrent/metastatic cervical most cancers (i.e., one of many deadliest cancers). Now, Seagen continues to be working a confirmatory Phase 3 open-label, randomized, international scientific trial dubbed innovaTV 301.

I forecasted 75% (extraordinarily favorable) probabilities of optimistic knowledge outcomes which might grant additional approval within the area the place Zai Lab operates — Mainland China, Hong Kong, Macau, and Taiwan. Highly excited in regards to the partnership, the President & CCO (William Liang) enthused,

Zai Lab has a major presence treating ladies’s cancers in China, and Tivdak is a crucial addition to our oncology business portfolio. Treatments for cervical most cancers stay a major unmet want in China with roughly 110K new circumstances yearly, and at present there are few efficient therapeutic choices out there. We sit up for this collaboration with Seagen to make Tivdak out there for sufferers in China as we increase our oncology portfolio.

Aside from the aforementioned Phase 3 trial, Seagen is pushing Tivdak into early scientific improvement for first-line cervical most cancers utilization and for sure different stable tumors. Therefore, the administration is unlocking extra worth from the Tivdak franchise for the approaching years. Simply put, Tivdak (like different stellar medication of Seagen) is a fruiting tree that retains on yielding extra fruits.

Latest Operating Results

Shifting gears, you must examine the most recent efficiency. After all, the administration’s earlier efforts translated into the present working outcomes. You might imagine that previous outcomes don’t assure future efficiency. Nevertheless, it may possibly present robust indications on the place the corporate is heading.

Viewing the determine beneath, Seagen has posted phenomenal 2Q2022 sales growths. The product gross sales of Big Four got here in on the outstanding 24% (i.e., from $383M to $432M) year-over-year (“YOY”) charge. Adcetris and Padcev contributed to the strongest gross sales development.

While Tivdak didn’t publish spectacular figures, I consider that it will do a lot better sooner or later as a result of the Zai Lab collaboration would materialize over time. Moreover, changing into a first-line remedy would increase gross sales development. Overall, you possibly can anticipate that the uptrend tendencies for each revenues and product gross sales would proceed.

latest results


Figure 4: Latest operational outcomes

Going into year-end, you possibly can see that Seagen is projected to ship from $1.71B to $1.75B in revenues. It was revised from the earlier estimate of $1.66B to $1.74B. Moreover, Adcetris gross sales are anticipated to come back in greater (i.e., from $750M to $775M) than earlier trajectory.

Essentially, Adcetris is heading nearer and nearer to the land of blockbusters. Meanwhile, the upper revised estimate signifies that these medication are performing higher than market expectation. That is an effective signal indicating your funding thesis is enjoying out prudently.



Figure 5: Fiscal 2022 outlook

Competitor Landscape

Regarding competitors, Seagen’s ADCs are competing in opposition to standard chemoradiation therapies and immunotherapies. They’re the bread and butter therapies for most cancers that won’t go away. Notwithstanding, ADC represents an efficacious/protected strategy that confers aggressive benefits. Additionally, there are new remedy modalities that exert stronger aggressive strain than standard medication. I famous within the prior analysis,

There are novel therapies like CAR-T, CAR-NK, and CAR-macrophage. Notably, CAR-T is already permitted for blood cancers. Though these novel CARs haven’t been confirmed efficient for stable tumors, that is the place future developments are heading. You can wager there will likely be some CARs that will be extremely efficient in opposition to stable tumors. That apart, there are the tumor-infiltrating lymphocytes (i.e., TILs) of Iovance Biotherapeutics (IOVA) which have demonstrated sturdy efficacy for cancers. Regardless of the competitors, there’s all the time a robust demand for novel therapeutics. The oncology house is huge and thereby affords many blockbusters.

Financial Assessment

Just as you’d get an annual bodily in your well-being, it is vital to examine the monetary well being of your stock. For occasion, your well being is affected by “blood flow” as your stock’s viability relies on the “cash flow.” With that in thoughts, I’ll assess the 2Q2022 earnings report for the interval that ended on June 30.

As , Seagen procured $431.7M in income in comparison with $347.3M for a similar interval a yr prior. Of that determine, the web product gross sales are comprised of $431.7M whereas the royalty revenues are made from $39.1M and the collaborative agreements introduced in $26.6M. As such, the whole income grew by the outstanding 24.3% YOY.

That apart, the analysis and improvement (R&D) for the respective intervals registered $304.2M and $234.8M. I considered the 29.5% R&D enhance positively as a result of the money invested at this time can flip into blockbuster earnings tomorrow. After all, you must plant a tree to get pleasure from its fruits.

Additionally, there have been $134.8M ($0.73 per share) internet losses in comparison with $84.5M ($0.47 per share) internet declines for a similar comparability. As you possibly can see, the upper bills associated to R&D cuts into the underside line. Right now, a very powerful development metric for Seagen is its topline (i.e., income). Nevertheless, you possibly can anticipate the corporate to financial institution a internet revenue sooner or later as the corporate grows bigger to leverage the “economy of scale.”



Figure 6: Key monetary metrics

About the stability sheet, there have been $1.9B in money and investments. On prime of the $431.7M quarterly income and (in opposition to the $463.6M quarterly OpEx), there needs to be sufficient capital to fund operations for a few years. In a nutshell, the money place and income are fairly sturdy relative to the burn charge.

Valuation Analysis

It’s vital that you simply appraise Seagen to find out how a lot your shares are actually price. Before working our determine, I appreciated to share with you the next:

Wall Street analysts sometimes make use of a valuation technique coined Discounted Cash Flows (i.e., DCF). This valuation mannequin follows a easy plug-and-chug strategy. That apart, there are different valuation methods reminiscent of worth/gross sales and worth/earnings. Now, there is no such thing as a such factor without any consideration or fallacious strategy. The most vital factor is to be sure to use the correct approach for the suitable kind of shares.

Given that developmental-stage biotech has but to generate any revenues, I steer away from utilizing DCF as a result of it’s most relevant for blue-chip equities. For developmental biotech, I leverage the combos of each qualitative and quantitative variables. That is to say, I take into account the standard of the drug, comparative market analysis, probabilities of scientific trial success, and potential market penetration. For a medical diagnostic system, I concentrate on market penetration and gross sales. Qualitatively, I rely closely on my instinct and forecasting experience over the a long time.

Molecules and franchises

Market potential and penetration

Net earnings based mostly on a 25% margin

PT based mostly on 183.6M shares excellent and 10 P/E

“PT of the part” after acceptable low cost

Padcev for superior urothelial most cancers

$4B (Estimated from the $8.4B international urothelial most cancers market).

$1B $54.46 $49.01 (10% low cost as a result of it’s efficiently launched and is rising aggressively on the 44% clip).
Adcetris for lymphomas

$3B (Estimated from the worldwide $13.1B lymphomas market)

$750M $40.84 $36.75 (10% low cost as a result of it’s efficiently launched and is rising aggressively).
Tukysa for breast most cancers $5B (Estimated from the $55B breast most cancers market) $1.25B $68.08 $61.27 (10% low cost as a result of it’s efficiently launched and is rising aggressively).
Tivdak for cervical most cancers $4B (Estimated from the $12.6B cervical most cancers market. Raised my estimate from the prior $3B as a result of the corporate is pushing it abroad & getting it permitted as 1st-line) $1B $54.46 $49.01 (10% low cost as a result of it’s efficiently launched and rising).
Young pipeline property Will anticipate additional improvement N/A N/A N/A

The Sum of The Parts


Figure 7: Valuation Analysis

Potential Risks

Since funding analysis is an imperfect science, there are all the time dangers related together with your stock no matter its elementary strengths. More importantly, the dangers are “growth-cycle dependent.” At this level in its life cycle, the primary concern for Seagen is whether or not the corporate can proceed to ramp up gross sales development for the Big Four medicines.

The different danger is that if the corporate can achieve extra label growth for the permitted therapeutics. There can also be a priority that not all creating molecules (i.e., the opposite pipeline growth) would ship the nice scientific knowledge wanted for approval.


In all, I preserve my purchase suggestion on Seagen with a 5/5 stars score. Seagen is a narrative of funding success that rewards long-term buyers. Over the years, the corporate efficiently launched its Big Four medication (Padcev, Adcetris, Tukysa, and Tivdak). Interestingly, these molecules are actually both the first-line remedy or the usual of take care of varied cancers. Meanwhile, the corporate continues to aggressively increase their labels and penetrate into new markets.

The current Zai Lab collaboration is an instance of prudent growth into the huge SouthEast Asia market the place there’s a excessive demand for Tivdak. The cope with LAVA can also be stable proof within the pudding that Seagen is extremely formidable to develop past its Big Four. That apart, recent knowledge reported have been robust. Going ahead, I anticipate extra optimistic scientific outcomes and regulatory choices from Seagen.

Source link


Please enter your comment!
Please enter your name here